Who Paid My Doc
Wilson Ray
Neurological Surgery Saint Louis, MO Medical Doctor
NPI 1669575619 CMS profile 301903
1044 N Mason Rd, Dept Neurological Surgery, Ste 110, Saint Louis, MO 63141
General payments
$586,295
Research payments
$0
Ownership & investment interest
$167,131
Research they led as principal investigator
$260,655
Through program year 2025, Wilson Ray of Saint Louis, MO is reported in the CMS Open Payments database as having received $586,295 across 466 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $260,655 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $167,131 across 6 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
13 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $160,766 | 88 | |
| 2024 | General | $114,287 | 111 | |
| 2023 | General | $60,816 | 57 | |
| 2022 | General | $55,806 | 42 | |
| 2021 | General | $62,019 | 63 | |
| 2020 | General | $38,400 | 37 | |
| 2019 | General | $94,201 | 68 | |
| 2025 | Ownership | $53,499 | 1 | |
| 2024 | Ownership | $39,693 | 1 | |
| 2023 | Ownership | $29,458 | 1 | |
| 2022 | Ownership | $19,750 | 1 | |
| 2021 | Ownership | $2,500 | 1 | |
| 2019 | Ownership | $22,231 | 1 |
Beside peers
- Wilson Ray
- Neurological Surgery median
- Middle half of Neurological Surgery
- National median
In program year 2025, general payments to Wilson Ray were reported at $160,766. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.
Show as a table
| Year | Wilson Ray | Neurological Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $94,201 | $582 | $138–$3,006 | $163 |
| 2020 | $38,400 | $294 | $76–$2,174 | $114 |
| 2021 | $62,019 | $387 | $105–$2,432 | $132 |
| 2022 | $55,806 | $542 | $139–$2,989 | $149 |
| 2023 | $60,816 | $534 | $145–$2,697 | $160 |
| 2024 | $114,287 | $574 | $155–$3,046 | $164 |
| 2025 | $160,766 | $596 | $159–$3,102 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 12 drugsPart D claims
563
Drug cost
$6,954
Branded share of claims
4.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Pregabalin | Generic | 76 | $3,063 | |
| Mupirocin | Generic | 181 | $1,084 | |
| Oxycodone Hcl | Generic | 107 | $1,019 | |
| Gabapentin | Generic | 50 | $661 | |
| Cyclobenzaprine Hcl | Generic | 40 | $401 | |
| Methocarbamol | Generic | 26 | $257 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 14 | $173 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 12 | $95 | |
| Tramadol Hcl | Generic | 22 | $78 | |
| Amitriptyline Hcl | Generic | 11 | $74 |
The 10 drugs with the highest cost, of 12 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 49 billing codesPaid by Medicare
$216,058
Medicare patients
172
Services billed
517
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Depression | 31% | |
| Diabetes | 30% | |
| Ischemic heart disease | 30% | |
| Chronic kidney disease | 18% | |
| COPD | 17% | |
| Cancer | 17% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
466 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neurological Surgery in Missouri
Neill Wright
Neurological Surgery · Saint Louis, MO
Carlos Bagley
Neurological Surgery · Kansas City, MO
Kaywan Gamadia
Neurological Surgery · Cape Girardeau, MO
Camilo Molina
Neurological Surgery · Saint Louis, MO
Paul Santiago
Neurological Surgery · Saint Louis, MO
Daniel Scodary
Neurological Surgery · Saint Louis, MO
Related records
Neurological Surgery in Missouri
Practitioners in the same specialty and state, ranked by reported value.
All Neurological Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Missouri
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.